Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

Issue : The Pharmaceutical Journal, 9/16 August 2014, Vol 293, No 7822/3

Sort by: Newest first Oldest first A-Z Z-A

  • Anafranil overdose Subscription

    5 AUG 2014 15:16

    The summary of product characteristics for Anafranil (clomipramine hydrochloride; Novartis) slow-release tablets 75mg now states that rare cases of pharmacobezoar, of varying severity including fatal outcome, have been reported in association with overdose of sustained release Anafranil. Further information about the pharmacobezoar is available in the updated SPC.

  • Prednisolone shelf life Subscription

    5 AUG 2014 15:14

    The shelf life for Deltacortril (prednisolone; Alliance) and prednisolone (Alliance) gastro-resistant tablets 2.5mg has been increased from 24 to 36 months, according to the updated summaries of product characteristics.

  • Eliquis new indication Subscription

    5 AUG 2014 14:50

    Eliquis (apixaban; Bristol-Myers Squibb) is now indicated for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and prevention of reccurent DVT and PE, according to the updated summary of product characteristics. New information on the dosing of apixaban for these indications has also been added to the SPC.

  • Whistleblowing resource Subscription

    5 AUG 2014 14:48

    The charity, Pharmacist Support, has launched a new fact sheet for pharmacists about whistleblowing. It covers topics such as how to deal with bullying after whistleblowing or dismissal from work after whistleblowing. 

  • Adverse reactions for Roche's Herceptin Subscription

    5 AUG 2014 12:16

    Nasopharyngitis, thrombocytopenia, weight loss, anorexia, insomnia, paraesthesia, dysgeusia, stomatitis, palmar-plantar erythrodysesthesia syndrome and peripheral oedema are now listed as very common adverse reactions on the summary of product characteristics for Roche’s Herceptin (trastuzumab). Pleural effusion, pharyngitis and pneumonia are now listed as common adverse reactions.

  • July EMA decisions Subscription

    5 AUG 2014 12:14

    Janssen Cilag’s Imbruvica (ibrutinib) has been recommended for authorisation by the European Commission for the treatment of relapsed or refractory mantle cell lymphoma (MCL) and chronic lymphocytic leukaemia (CLL), in this month’s decisions from the European Medicines Agency (EMA). Gilead’s Zydelig (idelalisib) has also been recommended for approval for the treatment of patients with CLL and patients with refractory follicular lymphoma.

  • Buccolam oromucosal solution recall Subscription

    5 AUG 2014 12:02

    The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a medicines recall for specific batches of ViroPharma’s Buccolam oromucosal solution (midazolam hydrochloride). This is because a routine inspection of the company’s contract manufacturing site in the UK identified the possibility of chemical contamination. Further information is available from the

  • Klaricid tablets discontinued Subscription

    5 AUG 2014 11:59

    Abbott has discontinued Klaricid (clarithromycin) tablets 250mg x 14 and 500mg x 14. Further information on 01628 773355.

  • Leflunomide recall Subscription

    5 AUG 2014 11:58

    The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a company-led drug recall for a specific batch of leflunomide (Medac) film-coated tablets 20mg. This is because the affected batch, which has inadvertently been distributed in the UK, is labelled for Poland/The Czech Republic/Slovakia. Further information is available from the

  • Changes to vaccine schedules Subscription

    5 AUG 2014 11:12

    Public Health England has announced changes to the meningococcal C conjugate vaccination schedule. The primary vaccine should now be given to infants at three months, and boosters should be given at 12–13 months, around 14 years and to first-time university entrants from 1 August 2014. More detail is available on the PHE website.

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.